External medication for skin
Patent 4879274 Issued on November 7, 1989. Estimated Expiration Date: 
November 7, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
November 7, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorsAssigneeApplicationNo. 906375 filed on 09/12/1986US Classes:514/12, 25 or more peptide repeating units in known peptide chain structure424/449, Transdermal or percutaneous514/29, The hetero ring has exactly 13 ring carbons (e.g., erythromycin, etc.)514/31, The hetero ring has 20 or more ring carbons (e.g., nystatin, etc.)514/39, Three or more saccharide radicals (e.g., neomycin, etc.)514/52, Phosphorus containing (e.g., Vitamin B12, etc.)514/110, Phosphorus is part of a ring514/152, 3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) DOAI514/154, With an additional active ingredient (excludes reaction product or complex)514/167, 9,10-seco- cyclopentanohydrophenanthrene ring system (e.g., vitamin D, etc.) DOAI514/174, -O-C-O- is part of a hetero ring (e.g., acetonide, etc.)514/178, Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/179, Modified C-ring (except methyl in 13-position) (e.g., double bond containing, substituted, etc.)514/180, 9-position substituted514/182, Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/262.1, Exactly four ring nitrogens in the bicyclo ring system514/270, Barbituric acid or derivative (including thioanalogs)514/271, Two or more barbituric acid compounds or with an additional active ingredient or stabilizer514/274, Chalcogen bonded directly to pyrimidine at 2-position514/280, Pentacyclo ring system having the six-membered hetero ring as one of the cyclos514/282, One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)514/295, Two of the cyclos share at least three ring carbons (i.e., bridged) (e.g., benzomorphans, etc.)514/301, Ring sulfur in the bicyclo ring system514/312, Chalcogen attached directly to the six-membered hetero ring by nonionic bonding514/356C=O in a C(=O)O group (e.g., nicotinic acid, etc.)ExaminersPrimary: Berch, Mark L.Attorney, Agent or FirmInternational ClassA61K 047/00Foreign Application Priority Data1985-09-27 JPAbstractNovel external medications comprise, as essential components, the following three components (A) to (C):(A) an -monoglyceryl ether represented by the following formula (I): ##STR1## wherein R means an alkyl or alkenyl group having 10 - 24 carbon atoms; (B) a physiologically active material; and(C) an oily material.The external medications have extremely high skin occlusive properties and significantly-improved absorptivity of phosiologically active materials. Therefore, a smaller amount of the medications compared with the conventional ones can give sufficient pharmacological effects and thus side effects can be reduced. The external medications may contain physiologically active materials such as drugs, growth hormones and the like, which are expected to show pharmacological effects upon their percutaneous absorption.Other References
Field of SearchTransdermal or percutaneousTopical application 25 or more peptide repeating units in known peptide chain structure The hetero ring has exactly 13 ring carbons (e.g., erythromycin, etc.) The hetero ring has 20 or more ring carbons (e.g., nystatin, etc.) Three or more saccharide radicals (e.g., neomycin, etc.) Phosphorus containing (e.g., Vitamin B12, etc.) Phosphorus is part of a ring 3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) DOAI With an additional active ingredient (excludes reaction product or complex) 9,10-seco- cyclopentanohydrophenanthrene ring system (e.g., vitamin D, etc.) DOAI -O-C-O- is part of a hetero ring (e.g., acetonide, etc.) Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system Modified C-ring (except methyl in 13-position) (e.g., double bond containing, substituted, etc.) 9-position substituted Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system Barbituric acid or derivative (including thioanalogs) Two or more barbituric acid compounds or with an additional active ingredient or stabilizer Chalcogen bonded directly to pyrimidine at 2-position | |
